|1.||Young, Tai-Horng: 2 articles (01/2015 - 10/2014)|
|2.||Fosså, Sophie D: 2 articles (05/2011 - 04/2011)|
|3.||Dahl, Alv A: 2 articles (05/2011 - 04/2011)|
|4.||Lehne, Gustav: 2 articles (05/2011 - 04/2011)|
|5.||Langberg, Carl W: 2 articles (05/2011 - 04/2011)|
|6.||Andersson, Stein: 2 articles (05/2011 - 04/2011)|
|7.||Skaali, Tone: 2 articles (05/2011 - 04/2011)|
|8.||Labow, Rosalind S: 2 articles (03/2009 - 06/2007)|
|9.||Balachander, Gowri Manohari: 1 article (12/2015)|
|10.||Rangarajan, Annapoorni: 1 article (12/2015)|
02/01/2008 - "We believe that this report is a case with the longest interval from TCPS to Fontan in which PAVF was diminished and marked cyanosis was improved."
02/01/2008 - "Marked cyanosis (pulse oximetry measuring 74%) progressed 8 years after TCPS because of the prominent development of bilateral pulmonary arteriovenous fistula (PAVF), which was diminished after the Fontan conversion, and recent pulse oximetry measured 95% 22 months after the conversion. "
11/01/1999 - "Conversion from total cavopulmonary shunt (TCPS) to the Fontan circulation can improve cyanosis in patients with potential risks of development of pulmonary arteriovenous fistula (PAVF). "
11/01/2009 - "To study the theoretical dose escalation based on the delineation of BTV, tumor control probabilities (TCPs) and normal tissue complication probabilities (NTCPs) of bladder and rectum were calculated and compared between the treatment plans. "
04/01/2009 - "By comparing the two tumor control probabilities (TCPs) from each study, we calculated the HT-related log cell-kill and then expressed it in terms of the number of 2 Gy fraction equivalents, for a range of tumor volumes and radiosensitivities. "
01/01/2015 - "TCPs resulting from these DVHs were estimated using a wide range of alphas, betas, and tumor cell densities. "
09/01/2014 - "Normal tissue complication probabilities (NTCPs), equivalent uniform doses (EUDs), and tumor control probabilities (TCPs) were studied for organs at risk (OARs) and target volumes of eight patients. "
10/01/2010 - "Strategies 2 and 3 gave EUDs and TCPs close to that of strategy 1, with strategy 3 being slightly better than strategy 2. Even greater benefits from strategies 1 and 3 are expected with increasing tumor movement or deformation during treatment. "
|3.||Testicular Neoplasms (Testicular Cancer)
05/01/2011 - "We prospectively explored self-reported cognitive problems in testicular cancer patients (TCPs) treated with and without chemotherapy. "
04/01/2011 - "To study the level of cancer-related distress (CRD) and variables associated with CRD in recently diagnosed testicular cancer patients (TCPs), and to explore associations between distress levels and neuropsychological test performance at the same time-point. "
05/01/2011 - "In testicular cancer patients (TCPs) treated with cisplatin-based chemotherapy, only few cross-sectional studies have addressed this concern. "
|4.||Hepatocellular Carcinoma (Hepatoma)
07/01/2013 - "The purpose of this study was to seek radiation dose responses separately for primary hepatocellular carcinoma (HCC) and metastatic (MET) colorectal liver tumours to establish tumour control probabilities (TCPs) for radiotherapy (RT) of liver tumours. "
09/01/2013 - "We have therefore created a novel suspension culture system, by seeding H35 rat hepatoma cells, a hepatocyte-derived cell line, in a 24-well tissue culture polystyrene (TCPS) plate placed atop an orbital shaker to create 3D spheroids. "
|5.||Foreign Bodies (Foreign Body)
03/01/2009 - "The study results suggested that U937 cells seeded onto DBP reacted with an altered, more mild, foreign body response than cells cultured on either PDMS or TCPS. "
01/16/2007 - "Since there was a high amount of cell death (due to either apoptosis or necrosis), and the foreign body response is a form of chronic inflammation, an 18 cytokine Luminex panel was performed on the supernatant from macrophages adherent on nPTFE and TCPS. "
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|8.||Thiobarbituric Acid Reactive Substances
|2.||Drug Therapy (Chemotherapy)
|3.||Right Heart Bypass (Cavopulmonary Anastomosis)
|4.||Colonic Pouches (S Pouch)
|5.||Fontan Procedure (Fontan Operation)